Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuanyuan, Zhang, Xiaolong, Lin, Fangzhen, Xiong, Mengshang, Fan, Dongmei, Yuan, Xiangfei, Lu, Yang, Song, Yuewen, Zhang, Yizi, Hao, Mu, Ye, Zhou, Zhang, Yanjun, Wang, Jianxiang, Xiong, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://www.ncbi.nlm.nih.gov/pubmed/31023384
http://dx.doi.org/10.1186/s13045-019-0723-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://www.ncbi.nlm.nih.gov/pubmed/31023384
http://dx.doi.org/10.1186/s13045-019-0723-8

Ejemplares similares